Aligos inks Greater China HBV drug deal with $25m upfront, $420m potential
Aligos Therapeutics granted exclusive Greater China rights to its HBV drug pevifoscorvir sodium under a licensing pact with Xiamen Amoytop, securing a $25m upfront payment. The deal offers up to $420m in milestones, tiered high-single-digit royalties and extends Aligos’ cash runway into late 2026.
1. Licensing Deal Terms
Aligos Therapeutics granted Xiamen Amoytop exclusive rights to develop and commercialise pevifoscorvir sodium for chronic hepatitis B in Hong Kong, Macau, Mainland China and Taiwan. The agreement provides a $25m upfront payment, potential $420m in clinical, regulatory and sales milestones, tiered high single-digit royalties and is set to close within 30 days pending shareholder approval.
2. Development Rights and Pipeline
Aligos retains all development and commercialisation rights for pevifoscorvir sodium outside Greater China, including Europe, Japan, South Korea and the US. The company will lead clinical trials in Greater China, with the Phase II B-SUPREME study comparing pevifoscorvir to tenofovir disoproxil fumarate and a second interim analysis due in H2 2026.
3. Financial Impact and Timeline
The upfront and potential milestone payments are expected to support Aligos’ operations through Q4 2026 under its current plan. Final top-line Phase II data are anticipated in 2027, with tiered royalties providing an ongoing revenue stream once commercialisation begins.